Benznidazole

Benznidazole is an antiparasitic medication used to treat infection with Trypanosoma cruzi, the parasite that causes Chagas disease. It is a nitroimidazole compound that acts as a prodrug; after uptake by the parasite, the nitro group is reduced by parasite nitroreductases to reactive metabolites that damage the parasite’s DNA and proteins, leading to death of the organism.

Medical use and effectiveness: Benznidazole is used for acute Chagas disease and for congenital infection. In the early chronic phase, it may be used with the goal of reducing parasite burden and slowing disease progression, but evidence for clear benefit in established chronic disease is limited and guidelines vary by region. The drug is most effective when treatment begins early in infection.

Administration and dosing: In adults, the typical regimen is 5–7 mg/kg per day, given in two divided doses for 60 days. Pediatric dosing follows a similar mg/kg basis and duration, though exact regimens may differ by country or program. Dosing and monitoring should follow local guidelines and medical supervision.

Adverse effects and safety: Common side effects include rash or dermatitis, fever, malaise, anorexia, weight loss, and nausea. Neurological effects such as peripheral neuropathy or dizziness can occur, as can hepatotoxicity or hematologic abnormalities in rare cases. The drug should be used with caution in liver disease, and patients are usually monitored during treatment. During pregnancy, benznidazole is generally avoided due to potential risks to the fetus; contraception is often advised during therapy.

Regulatory status: Availability varies by country. Benznidazole is not universally approved everywhere and may be used under national programs, clinical trials, or special access schemes rather than as a standard prescription in some regions.